TAGAMET HB LABELING SECTION FOR QUANTITATIVE EFFICACY INFORMATION
This article was originally published in The Tan Sheet
TAGAMET HB LABELING SECTION FOR QUANTITATIVE EFFICACY INFORMATION is being considered in discussions between FDA and SmithKline Beecham, FDA Office of Drag Evaluation I Director Robert Temple, MD, indicated July 27 at a joint meeting of the agency's Gastrointestinal Drugs and Nonprescription Drugs Advisory Committees. Temple asked the committees to consider "whether there should be an attempt to give some description of just how much benefit there is" from OTC cimetidine for heartburn.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC